leadf
logo-loader
RNS
viewe-Therapeutics PLC

e-Therapeutics plc - Director/PDMR Shareholding

RNS Number : 1435T
e-Therapeutics plc
16 July 2020
 

E-THERAPEUTICS PLC

 

("e-therapeutics" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

 

                                                                                   

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Ali Mortazavi

2

Reason for the notification

a)

Position/status 

Executive Chairman

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary shares of 0.1 pence

 

ISIN:   GB00B2823H99

b)

Nature of the transaction

Purchase of new shares as part of a placing

 

c)

Price(s) and volume(s)

1,666,666 ordinary shares at a price of 12 pence per share

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

15 July 2020 

f)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Michael Bretherton

2

Reason for the notification

a)

Position/status 

Non-Executive Director

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary shares of 0.1 pence

 

ISIN:   GB00B2823H99

b)

Nature of the transaction

Purchase of new shares as part of a placing

c)

Price(s) and volume(s)

500,000 ordinary shares at a price of 12 pence per share

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

15 July 2020 

f)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Trevor Jones

2

Reason for the notification

a)

Position/status 

Non-Executive Director

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary shares of 0.1 pence

 

ISIN:   GB00B2823H99

b)

Nature of the transaction

Purchase of new shares as part of a placing

c)

Price(s) and volume(s)

50,000 ordinary shares at a price of 12 pence per share

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

15 July 2020 

f)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information, please contact:

 

e-therapeutics plc

Ali Mortazavi, Executive Chairman

Laura Roca-Alonso, Chief Business Officer

 

Tel: +44 (0) 1993 883 125

www.etherapeutics.co.uk 

 

Numis Securities Limited

Freddie Barnfield/Duncan Monteith (Nominated Adviser)

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000

www.numis.com

 

FTI Consulting

Simon Conway/Stephanie Cuthbert

Tel: +44 (0) 207 727 1000

Email: e-therapeutics@fticonsulting.com

 

 

About e-therapeutics plc

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

 

e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.

 

e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFLFIADDIELII

Quick facts: e-Therapeutics PLC

Price: 16.005

Market: AIM
Market Cap: £67.07 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE